Navigating Europe's AI regulatory labyrinth: A strategic gui...
For US drug developers, bringing AI tools across the Atlantic introduces steep regulatory hurdles.
Newsletters and Deep Dive digital magazine
For US drug developers, bringing AI tools across the Atlantic introduces steep regulatory hurdles.
Roviant & Priovant Therapeutics finally secure US approval for once-daily oral TYK2/JAK1 inhibitor, Lisraya (brepocitinib), for dermatomyositis.
FDA has approved the 2026 COVID vaccine formulations, but last year's narrower recommendation stands, leaving open questions about access.
For biotech sponsors, the question worth asking is not whether the rebound is real, but what it is actually rewarding.
The US FDA has green lit ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 in children weighing at least 2 kg.
Editor's Picks
Newsletters and Deep Dive
digital magazine